Clostridium Difficile Diagnostics and Treatment Market is Expected to Gain Popularity Across the Globeembed
The global clostridium difficile diagnostics and treatment market was valued at US$ 1,272.2 million in 2016 and is expected to witness a robust CAGR of 8.2% over the forecast period (2017–2025).
Clostridium Difficile Diagnostics and Treatment Market Review, Outlook, Future Analysis And Synthesis By 2025 Clostridium difficile is a disease caused by bacteria. Symptoms of the disease includes diarrhea, nausea, colon inflammation, and others. Clostridium difficile infection affects older adults, and according to Centers for Disease Control and Prevention (CDC), 2015, clostridium difficile infection is the most common healthcare-associated infection. Furthermore, frequent use of antibiotic medication is also responsible for clostridium difficile infection, as antibiotics kill normal flora (good bacteria) and allow for multiplication of C. difficile bacteria. Common symptoms of clostridium difficile infection include watery diarrhea, dehydration, fever, nausea, loss of appetite, and weight loss. Life threatening symptoms of the disease includes abdominal distension, severe abdominal pain, and profuse diarrhea. Clostridium difficile infection management includes diagnosis of the infection using various tests and medication therapies using antibiotics such as Vancomycin and Fidaxomicin. Request For Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1499 Market Dynamics Factors such as rising prevalence of clostridium difficile infection, availability of precise and advanced diagnostic techniques such as real time-polymerase chain reaction (RT-PCR), and presence of generic versions of standard antibiotics such as metronidazole is expected to boost growth of the clostridium difficile diagnostics and treatment market over the forecast period. Furthermore, various organizations and manufacturers are working towards increasing awareness about clostridium difficile infection and its severity. For instance, in March 2018, C Diff Foundation awarded its “Making a Difference” award to CutisPharma, Inc.—a pharmaceutical company, for contribution of the company towards increasing awareness and expanding treatment options. Rising prevalence of clostridium difficile infection is expected to boost growth of the market over the forecast period Incidence of clostridium difficile infection has been witnessing an increase in the recent past, due to clostridium difficile infection recurrence and antibiotic resistance. According to Centers for Disease Control and Prevention (CDC), 2015, around half a million people in the U.S. suffer from clostridium difficile infection in a year. Moreover, according to National Center for Biotechnology Information (NCBI), an estimated 37,900 patients were suffering from clostridium difficile infection in Canada in 2012. A review and meta-analysis of studies published in National Center for Biotechnology Information (NCBI), 2016, conducted in China between 2010 and 2016 showed significant incidence of clostridium difficile infection in China. Furthermore, according to Canadian Antimicrobial Resistance Surveillance System 2017 Report, clostridium difficile infection may be a consequence of commonly prescribed antibiotics for unrelated infections. According to Organization for Economic Co-operation and Development (OECD), 2015, antibiotic resistant bacteria are highly prevalent in G7 countries. This high presence of antibiotic resistant bacteria may lead to increasing incidence of the infection, which in turn is expected to aid in growth of the global clostridium difficile diagnostics and treatment market. The global clostridium difficile diagnostics and treatment market was valued at US$ 1,272.2 million in 2016 and is expected to witness a robust CAGR of 8.2% over the forecast period (2017–2025). Report includes chapters which deeply display the following deliverable about industry : • Clostridium Difficile Diagnostics and Treatment Market Research Objective and Assumption • Clostridium Difficile Diagnostics and Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Clostridium Difficile Diagnostics and Treatment Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Clostridium Difficile Diagnostics and Treatment Market, By Regions • Clostridium Difficile Diagnostics and Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Clostridium Difficile Diagnostics and Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Clostridium Difficile Diagnostics and Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Clostridium Difficile Diagnostics and Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Top Key Players Some major players operating in the clostridium difficile diagnostics and treatment market include Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Alere, Inc., Trinity Biotech, Summit Therapeutics, Baxter International Inc., Sanofi S.A., Novartis AG, and AstraZeneca Plc. Detailed Segmentation: Global Clostridium Difficile Diagnostics and Treatment Market, By Product Type: By Drug • Metronidazole • Vancomycin • Fidaxomicin • Bezlotoxumab By Diagnostic Test • Enzyme Immunoassays • Real-Time Polymerase Chain Reaction (RT-PCR) • Nucleic Amplification Tests (NAAT) • Others Global Clostridium Difficile Diagnostics and Treatment Market, By Distribution Channel: • Hospitals & Clinics • Diagnostic Laboratories • Pharmacies Browse Full Report @ https://www.coherentmarketinsights.com/marketinsight/clostridium-difficile-diagnostics-and-treatment-market-1499 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]